GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-08-04| Partnerships

Amgen Lays Down $3.7 Billion For ChemoCentryx and its Autoimmune Portfolio

by Max Heirich
Share To

Amgen announced on August 4 that they would purchase a biopharmaceutical company called ChemoCentryx. The definitive agreement of the acquisition outlines that each share of ChemoCentryx will sell for $52 in cash, totaling $3.7 billion. The deal closes in the last quarter of 2022.

Related Article: Quince Therapeutics Overview for Strategic Growth

What ChemoCentryx Brings to the Table

ChemoCentryx and Amgen are companies that focus on developing treatments for autoimmune diseases, inflammatory disorders, and cancer. Specifically, Amgen is interested in ChemoCentryx’s recently approved treatment for autoimmune inflammatory diseases known as TAVNEOS.

TAVNEOS, an orally administered therapy, treats patients suffering from ANCA-associated vasculitis as a complementary treatment to standard therapy. ANCA-associated vasculitis is a broad term classifying a group of multi-system autoimmune diseases with small vessel inflammation. These conditions lead to injury and dysfunction in the kidneys, lungs, and other organs when left untreated. 

In addition to TAVNEOS’ recent U.S. Food and Drug Administration (FDA) approval in October 2021, ChemoCentryx is currently developing three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral checkpoint inhibitor for cancer. These treatments align with Amgen’s portfolio of inflammation treatments, such as Otezla®, ENBREL®, TEZSPIRE®, and others. 

Acquisition to Close by the Year’s End

Both boards of directors for Amgen and ChemoCentryx unanimously approved the acquisition for $52 per share in cash, totaling $3.7 billion. However, the transaction requires ChemoCentryx shareholders’ final approval, regulatory approvals, and other customary closing conditions. 

On the acquisition, Thomas J. Schall, Ph.D., the president and chief executive officer of ChemoCentryx, said, “A fierce commitment to improving human lives is the bond that unites Amgen and ChemoCentryx today. It is an honor to now join Amgen’s great mission, and together begin a bright new era bringing landscape-shaping medicines like TAVNEOS to those who will benefit most.”

Should the acquisition be approved, the deal will close in the fourth quarter of 2022. 

Related Article: Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
M&A
Big Pharma’s Next Move: BMS, Merck, Amgen Eye M&A to Tackle Patent Expirations
2024-11-14
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top